Ixaka

About:

Ixaka is a private cell and gene therapy company with a focus on the natural power of the body to cure disease.

Website: https://www.ixaka.com/

Twitter/X: _rexgenero

Top Investors: Innovate UK, ZenPharma Limited

Description:

Ixaka is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease. Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.

Total Funding Amount:

$72.7M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2015-01-01

Contact Email:

info(AT)ixaka.com

Founders:

Gaby Salem, Joe Dupere, Vicente Sáez González

Number of Employees:

51-100

Last Funding Date:

2021-01-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai